Company: NCNA
Filing Date: 2025-04-04
Form Type: DRS
Source: 0000950123-25-003335
Chunk: 20

Company: NuCana plc
Filing Date: 2025-04-04
Form: DRS
Chunk 20
---
 investment decision based on these estimates and forward-looking statements. 11

Confidential Treatment Requested by Nucana plc

Pursuant to 17 C.F.R. Section 200.83

Website Disclosure

We maintain a public website at https://www.nucana.com and use our website as a routine channel of distribution of company information,
including press releases, analyst presentations, and supplemental financial information, as a means of disclosing material non-public information and for complying with our disclosure obligations under
Regulation FD. Our website includes an Investors section through which we make available, free of charge, our Annual Reports on Form 20-F, Reports on Form 6-K, as well
as any amendments to those reports filed or furnished pursuant to the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Accordingly, investors should monitor our website in
addition to following press releases, filings with the SEC, and public conference calls and webcasts.

None of the information provided on
our website, in our press releases or public conference calls and webcasts or through social media is incorporated into, or deemed to be a part of, this prospectus or in any other report or document we file with the SEC, and any references to such
website is intended to be inactive textual references only.

12

Confidential Treatment Requested by Nucana plc

Pursuant to 17 C.F.R. Section 200.83

USE OF PROCEEDS

We estimate that the net proceeds from our issuance and sale of our securities in this offering, assuming all the securities we are offering
are sold, will be approximately $ million, based on an assumed combined public offering price of $ per ADS and accompanying Warrants, which was the closing price of our ADSs on The Nasdaq Capital Market on
, 2025 after deducting Placement Agent fees and estimated offering expenses payable by us assuming no sale of any Pre-Funded Warrants and no exercise of the Warrants. Based on
the assumed offering price set forth above, we estimate that our net proceeds from the sale of 75%, 50%, and 25% of the securities offered in this offering would be approximately $ million, $ million and
$ million, respectively, after deducting the estimated Placement Agent fees and estimated offering expenses payable by us, and assuming no issuance of any Pre-Funded Warrants and assuming no
exercise of the Warrants.

However, because this is a best efforts offering